Reauthorization of the PRV program provides multi-year policy certainty and a monetizable voucher that can deliver significant non-dilutive funding upon sale. Absent a PRV-like mechanism, UK ...

Sentynl holds an exclusive U.S. commercialization option for AATD-LD, while securing global manufacturing rights; Mereo retains commercial rights outside the U.S. and leads Phase III execution.

Consideration includes $820 million upfront and up to $500 million in approval and sales milestones, with financing expected from cash on hand and existing credit facilities. ABS-1230 is a ...

In July of this year, Krieger Scientific issued a release addressing the increase in 303 drug warning letters issued by FDA. In 2025, as new leadership took over the agency, FDA sent 303 drug warning ...

Last week, reports emerged of a potential merger between AstraZeneca and Bristol Myers Squibb. While a senior source reportedly debunked these rumors days later, the news caused an uproar across the ...

In today's Pharmaceutical Executive Daily, Jazz Pharmaceuticals agrees to acquire Actio Biosciences, Novo Nordisk, Innate Pharma, and Innovent Biologics strike a trio of new partnerships, and a Veeva ...

We have been telling ourselves a story about pharma communications for the past 20 years. The story goes like this: Global ...

Even products with a competitive advantage underperform three-year consensus targets 29% of the time; product superiority ...

FDA authorization covers adults ≥50, positioning mFLUSIVA as Moderna’s first mRNA influenza vaccine and expanding its US ...

Such enterprises will be defined not only by breakthrough therapies but also by agile leadership, AI-enabled transformation and patient-centered operating models that accelerate innovation into ...

Rumored tie-up implies acquirer skepticism versus target premium, with AstraZeneca shares falling sharply while BMS rose, reflecting concerns about value transfer and integration risk. A major ...